MedTrace Logo

Combination of Hypofractionated Proton Therapy With Immunotherapy

NCT03764787 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-12-05

No results posted yet for this study

Summary

The purpose of this research study is to compare the effects (good and bad) on subjects and their cancer using hypofractionated proton radiation therapy in combination with immunotherapy(ie. Programmed cell death protein 1, also known as PD-1 antibody). Hypofractionation is a technique that delivers higher daily doses of radiation over a shorter period of time.

Conditions

  • Proton Therapy
  • Immunotherapy

Interventions

COMBINATION_PRODUCT

Radiation+PD-1 Ab

combination of proton radiotherapy with PD-1 antibody

Sponsors & Collaborators

  • YiZhou International Cancer Hospital

    collaborator UNKNOWN

  • Peking University First Hospital

    lead OTHER

Principal Investigators

  • Xianshu Gao, MD,PhD · Peking University First Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2021-01-01
Completion
2021-12-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03764787 on ClinicalTrials.gov